Bispecific peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism
A first-in-class bispecific antibody-peptide conjugate developed at Amgen that pairs a fully human monoclonal glucose-dependent insulinotropic polypeptide receptor antagonist antibody with two covalently linked glucagon-like peptide 1 analogue agonist peptides, yielding a long-acting once-monthly injectable for chronic weight management distinguished from existing incretin therapeutics by simultaneous GIP receptor blockade and an approximately 21-day elimination half-life.
Abstract
Maridebart cafraglutide (MariTide; development code AMG 133) is a first-in-class bispecific peptide-antibody conjugate engineered at Amgen by covalent attachment of two glucagon-like peptide 1 (GLP-1) receptor agonist peptide analogues to a fully human immunoglobulin G2 (IgG2) monoclonal antibody that functions as a potent antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). The molecule was designed to exploit the additive weight-loss pharmacology of simultaneous GLP-1 receptor (GLP-1R) activation and GIP receptor blockade, a mechanistic combination that in preclinical diet-induced obese mouse and cynomolgus monkey models produced greater body-weight reduction than either moiety alone. In cell-based functional assays the compound demonstrates GLP-1R agonist activity with EC50 values of 24.4 picomolar (human), 5.7 picomolar (cynomolgus monkey), 2.4 picomolar (rat), and 123 picomolar (mouse), and GIPR antagonist activity with IC50 values of 46.4 nanomolar (human), 26.5 nanomolar (cynomolgus monkey), and 822.3 nanomolar (rat) [1, 2]. The antibody scaffold confers a terminal elimination half-life of approximately 21 days in humans after subcutaneous administration, approximately three-fold longer than the longest-acting approved once-weekly GLP-1 receptor agonists, and supports once-monthly or less frequent dosing [1]. In a Phase 1 randomized, double-blind, placebo-controlled single- and multiple-ascending-dose study (NCT04478708) in 163 adults with obesity, maridebart cafraglutide produced dose-dependent weight loss of up to 14.5 percent at 12 weeks with weight loss maintained for up to 150 days after the final dose, accompanied by an acceptable safety and tolerability profile in which gastrointestinal adverse events (nausea, vomiting) were predominantly mild and transient [1]. The Phase 2 study further reported no clinically significant changes in bone mineral density and body-composition data indicating that the majority of weight lost was fat mass rather than lean tissue. Amgen initiated the Phase 3 MARITIME program in 2025, comprising chronic weight management trials (MARITIME-1 in obesity without type 2 diabetes, MARITIME-2 in obesity with type 2 diabetes) with planned 72-week treatment duration and primary readouts expected in early 2027, as well as planned Phase 3 cardiovascular outcomes, heart failure, and obstructive sleep apnea studies [5, 6]. The compound is not approved by any regulatory authority as of the monograph date. This monograph reviews the chemistry, mechanism, pharmacokinetics and analytical identity of the compound, with a curated reference list.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.